.@LudaBazhenovaMD, of @UCSDHealth, covered treatment and resistance with KRAS G12C inhibitors in NSCLC and highlighted MRTX1133 and RAS(ON), both KRAS G12D inhibitors. Still early stages but potential activity with RAS(ON) inhibitors in KRAS G12C-resistant disease #ILCC #lcsm (@OncLive)

Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC 💥KEAP1, SMARCA4 and CDKN2A mutations lead to shorter survival in lung cancer patients treated with KRAS-G12C inhibitors (@mvnegrao et al.) @CD_AACR @MDAndersonNews https://t.co/Vh2FY3pluD https://t.co/EvmUncUHrN (@dr_yakupergun)

#WCGIC2023 💊 Emerging targets in #GI cancer 🪑Dr. Van Cutsem and Dr. Carnero 🗣️ Dr. Strickler 🎯 kRAS inhibitors: Sotorasib, Adagrasib, Divarasib ⚠️ Adaptive feedback Increasing #SHP2 #EGFR #NRAS #HRAS ✔️ Dual or triple inhibition might overcome #Resistance #research @WCGIC (@DrMirallas)

Co-mutations in three tumor suppressor genes are independent determinants of poor clinical outcomes with KRAS G12C inhibitors in advanced non-small cell lung cancer https://t.co/hBmuPWL5nd #fondazionebonadonna #cancerresearch #oncology @CarmenCriscit @BianchiniGP @mauricallari (@FondazioneBona1)

AVM: SCARLET Study WJOG14821L Single arm Ph2 sotorasib + chemo in KRAS G12c nonsquamous mNSCLC 🔹N=30, chemo & KRAS inhibitor naive 🔹1ry endpoint ORR: 88.9% No diff in ORR by PD-L1 expression mPFS and mOS NR but limited f/u at analysis of only 4 mo #LCSM #ASCO23 @AnaVManana (@OncLive)

#OpenAccess in @MCT_AACR - preclinical studies with @pfizer KRAS G12C inhibitor in #PancreaticCancer xenograft & a new #LungCancer G12C autochthonous model. Responses in genetic models attenuated versus xenografts (no surprise). Metabolic imaging as PD. https://t.co/KfbKorOjVR (@Aiims1742)

Adagrasib in Advanced Solid Tumors Harboring a KRAS G12C Mutation. https://t.co/kMjwaxMfkz By @JCO_ASCO PMID: 37099736 “PURPOSE: Adagrasib, a KRASG12C inhibitor, has demonstrated clinical activity in patients with KRASG12C -mutated non-small cell lung cancer (NSCLC) and… https://t.co/YnCO0tpz9g (@vitor__moutinho)

KRYSTAL-1: Adagrasib in patients with advanced solid tumors harboring a KRAS G12C mutation. Comprehensive overview of KRAS G12C inhibitors, intrinsic/acquired resistance, and drug development in KRAS pathway by @ElenaGarralda @ASCO plenary. (@HHorinouchi)

#AACR23 | Chapin Theater-Convention Center | Monday CT028 - A First-in-Human Phase 1 Study of LY3537982, a Highly Selective and Potent KRAS G12C Inhibitor in Patients With KRAS G12C-mutant Advanced Solid Tumors @BeccaHeistMD ➡️ https://t.co/XuAsTtxZKd @AACR (@MGHCancerCenter)

Concurrent with #AACR23 in @CD_AACR Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC https://t.co/e5GPOPvOfF Key co-mutation data below in cohort of 424 patients. Important work by @MDAndersonNews crew @FSkoulidis @mvnegrao @DavidHongMD & many other colleagues. (@Aiims1742)

The #OncoAlertTopTweet 🚨 Day2⃣of @AACR #AACR23 Tweet by our @OncoAlert faculty @christine_lovly 🇺🇸 Dr. Janne from @DanaFarber summarizes #KRAS G12C inhibitors across numerous cancers. Current approvals of sotorasib + adagrasib in #lungcancer 🫁 best, @weoncologists (@OncoAlert)

Dr. Pasi Janne from @DanaFarber summarizes #KRAS G12C inhibitors across numerous cancers. Current approvals of sotorasib + adagrasib in #lungcancer. Efficacy varies across tumors of different origins and is limited by acquired resistance. #AACR23 @AACR @OncoAlert #LCSM (@christine_lovly)

BRAF inhibition is universally ineffective in colorectal cancer absent concurrent EGFR inhibition. We are seeing similar play out with KRAS inhibitors in CRC. This seems a question of tissue specific biology and pathway dependence. (@Labrat3)

Great discussion by Navneet Singh @ns_chd focused on how smoking impacts outcomes with KRAS inhibitors and how “it is never too late to quit smoking!” #ELCC2023 @IASLC @myESMO (@HwakeleeMD)

📢📢 On Behalf of my Co-Investigators 🤩🤩 to present ➡️Adargrasib (#KRAS G12C inhibitor) in solid tumors with #KRAS G12C mutation. 🙏🙏 @ASCO for the platform. ⏰ Join us Virtually 4/20 @3 PM EST ⏰ Presentation ➕ Q&A ➡️ Details https://t.co/JEXcePm5Rt (@DrShubhamPant)

1️⃣2️⃣ ✳️KRAS G12C is also now actionable ❗️ ✳️Unlike lung and PDAC, EGFR blockade is a must for the use of KRAS G12C inhibitors! If considering clinical for a CRC patient, look one with an EGFR blockade ! Otherwise off label use of Adagrasib and cetuximab offers good results ‼️ (@IbrahimSahinMD1)

For #KRASG12C #LCSM, we now have #Sotorasib ➡️ ORR: 37%, mDOR-11 mths ➡️ mPFS improvement vs docetaxel, although modest- hopefully will lead to improvement over this with upcoming agents/strategies! and #Adagrasib ➡️ ORR: 43%, mDOR: 9 mths! #ACSCancerChat @VSubbiah @nehakred (@ADesaiMD)

Sotorasib for Lung Cancers with KRAS p.G12C Mutation | NEJM @nejm https://t.co/m7EB2AP1qR (@VivekSubbiah)

Adagrasib/sotorasib definitely seem less active in CRC than NSCLC as single agents. I am still convinced that targeting KRAS will be key in both NSCLC and CRC. Excited about KRAS(ON) inhibitors, combinations. Still plenty of reason for optimism. (@JonathanOstrem)

A 12-4. G12Ci Combi recruiting #clinicaltrials 📌CodeBreak 300 https://t.co/5lOD1uqMFD 📌2L 📌Ph III 📌n=153 📌AMG510 (KRAS G12Ci) 2 diff doses + Vectibix vs TAS102 or Regorafenib 📌PFS end point 📌Exclusion: Prior G12Ci & active brain mets #CRCTrialsChat #CRCSM @OncoAlert (@PMBolandMD)

#Mechanisms leading to #resistance to #lung #cancer treatment with #Sotorasib, the first #KRAS inhibitor https://t.co/PVFGUdE5aA (@Dr_JJ_Berenguer)

Adjuvant osimertinib and other targeted therapies, such as KRAS G12C inhibitors, could continue to change the perioperative treatment landscape in non–small cell lung cancer. @DrAlexAdjei @ClevelandClinic #lcsm https://t.co/qtGgQKb6pv (@OncLiveSOSS)

Presidential session @JSMO_official. Prof. Isamu Okamoto presented Sotorasib versus Docetaxel for Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation: CodeBreaK 200. FREE on-demand access for international audiences! https://t.co/FOoy0D4CKL #JSMO2023 #LCSM (@HHorinouchi)

Presidential session @JSMO_official. Prof. Isamu Okamoto presented Sotorasib versus Docetaxel for Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation: CodeBreaK 200. FREE on-demand access for international audiences! https://t.co/M3njqk44vJ #JSMO2023 #LCSM (@HHorinouchi)

In this retrospective series, @GLambertiMD et al reported on intracranial activity of sotorasib in pts w/ #KRAS G12C mut #NSCLC ➡️ https://t.co/879diwFv5U @Oncoalert @DrMarkAwad #LCSM #JCOPO (@JCOPO_ASCO)

#PLCClive23 Dr. @kamarroneMD discusses management of #KRAS G12C NSCLC and how sotorasib and adagrasib fit into our treatment algorithms. What future combinations will rise to the top? Immunotherapy remains our first-line strategy; are IO combos safe? Stay tuned... (@StephenVLiu)

#Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial https://t.co/cYSbQsLcKN (@MLPOncoData)

“The results of this trial pave the way for further exploration of KRAS inhibitors in patients with NSCLC." Dr. Sarah Goldberg & @DrRoyHerbstYale discuss the trial in the Linked Comment. https://t.co/8zoMvVnbl1 (@TheLancet)

Julian Downward and colleagues developed a cell line derived from the Lewis Lung Carcinoma, 3LL ΔNRAS, which does not respond unless you use a KRas V12C inhibitor. B6 background. The problem is, you need to get the drug (or silence KRAS, I suppose) https://t.co/TqPBn1SE63 (@apoptosislab)

Sotorasib offers a small difference in median progression-free survival and better tolerability in advanced NSCLC with KRAS mutation. #lungcancer @TheLancet @bensolomon1 https://t.co/GhWG88yuD8 (@thelimbicresp)

SOTORASIB vs Docetaxel 2nd line mNSCLC with KRAS G12C Better ORR, PFS, QOL Fewer side effects @myESMO @KRASKickers @Bharadw78721902 @shikharkumar89 @RajeshBollam11 https://t.co/KWIFlsBEXN (@saadvikdr)

@IbiayiMD is currently presenting at the @IASLC #TTLC23: "BRAF+ #NSCLC and Resistance to KRAS G12C Inhibitors". #LCSM (@IASLC)

KRAS G12D inhibitors are on their way… ! Promising preclinical activity, a good news for patients with pancreatic cancer or other KRAS G12Dmut tumors (@mihaela_aldea)

Multiple orthogonal preclinical models of #PancreaticCancer were used here (human & murine cell lines, organoids, autochthonous models) showing activity of KRASG12D inhibition in advanced disease but remarkably also reversing EARLY precursors. Congratulations to the team! (@Aiims1742)

Multiple orthogonal preclinical models of #PancreaticCancer were used here (human & murine cell lines, organoids, autochthonous models) showing activity of KRASG12D inhibition in advanced disease but remarkably also reversing EARLY precursors. Congratulations to the team! (@Aiims1742)

Results of the phase 3 #CodeBreak200 trail finds that sotorasib increased PFS compared with docetaxel in those with #KRASG12C+ advanced #NSCLC 💊🫁 Read the full study in @TheLancet by Adrianus Johannes de Langen, @LuisPaz_Ares and colleagues! ➡️ https://t.co/0dKfrCAfiV (@LungSummit)

Sotorasib significantly increased PFS and had a more favourable safety profile, compared with docetaxel, in patients with advanced NSCLC with the KRASG12C mutation and who had been previously treated with other anticancer drugs. @LuisPaz_Ares https://t.co/ymmQfwk6D3 (@PazAresLab)

#FeatureFriday Today on #FeatureFriday we are featuring a tweet by Dr. Dipesh Uprety [ @dipeshuprety4 ] on how #Sotorasib significantly increased progression-free survival and has more safety profile, compared to #docetaxel, in patients with #KRASG12C mutated advanced #NSCLC. (@4baseCare)

Sotorasib 960 mg orally once daily,showed anticancer activity and had an acceptable safety profile in patients with KRAS p.G12C–mutated advanced pancreatic cancer who had received previous treatment. (@singhv2003)

Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial - ScienceDirect https://t.co/xzmFbnnjE0 (@lindamahj)

CodeBreak 200 @TheLancet: a phase 3 study of Sotorasib vs. Docetaxel in pts with previously treated KRAS G12C mutant NSCLC--> statistically significant 🫢increase in the PFS for sotorasib (Md PFS 5.6 mo vs 4.5 mo) #LCSM @OncoAlert https://t.co/YnIjLeQysK (@dipeshuprety4)

Out in @TheLancet today. Sotorasib significantly increased PFS (HR 0.66) and had a more favourable safety profile, compared with docetaxel, in pts with pretreated adv. NSCLC w. KRASG12C mutation https://t.co/YwSl7VBTR9 (@JulienMazieres)